Greater number of negative posttreatment biopsies seen among men with higher baseline genomic risk score<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Jan. 18, 2023 (HealthDay News) — For men with low- to intermediate-risk prostate cancer on active surveillance, the negative repeat biopsy rate is high following 90 days of apalutamide, according to a study published in the February issue of The Journal of Urology<\/em>.<\/p>\n Michael T. Schweizer, M.D., from the University of Washington in Seattle, and colleagues conducted an open-label, single-arm, phase II study testing 90 days of oral apalutamide daily in men with low- to intermediate-risk prostate cancer on active surveillance. The percentage of patients with a negative biopsy immediately following treatment was examined as the primary objective.<\/p>\n Of the 22 men who completed 90 days of apalutamide with posttreatment biopsy, 15 had Grade Group 1 disease and the others had Grade Group 2 disease; seven had favorable- to intermediate-risk disease (30 percent). The researchers found that on posttreatment biopsy, 13 of the patients (59 percent) had no residual cancer. There was a median of 364 days to first positive biopsy. A minimal and transient effect was seen for apalutamide on quality of life. A greater number of negative posttreatment biopsies was seen for those with a higher baseline genomic risk score in the decipher risk classifier.<\/p>\n “Of note, not only did low-risk patients appear to benefit, but we also saw favorable pathological effects in those with higher-risk features (i.e., Grade Group 2 disease, high genomic risk) — indicating that men at risk for needing local treatment could benefit from this approach,” the authors write.<\/p>\n Several authors disclosed financial ties to pharmaceutical companies, including Janssen, which manufactures apalutamide and provided drug and funding support for the study.<\/p>\n